| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $73.00 | Sell → Neutral | UBS |
| 3/11/2025 | $85.00 → $100.00 | Neutral → Buy | Goldman |
| 1/8/2025 | $95.00 → $103.00 | Hold → Buy | Jefferies |
| 9/26/2024 | $84.00 → $74.00 | Neutral → Sell | UBS |
| 9/18/2024 | $100.00 | Neutral → Buy | BTIG Research |
| 9/9/2024 | $90.00 | Neutral | JP Morgan |
| 8/6/2024 | $100.00 | Buy | Stifel |
| 5/30/2024 | $87.00 | Neutral | Goldman |
| 2/15/2024 | $100.00 | Buy | HSBC Securities |
| 2/12/2024 | $66.00 → $88.00 | Sell → Neutral | UBS |
GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy
3 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion. Behind the scenes, several new AI healthcare tech developments are taking place, with updates rec
The company will showcase innovations designed to optimize the oncology care workflow and enable improved patient outcomes GE HealthCare (NASDAQ:GEHC) today announced an intended expansion of its radiation oncology portfolio as well as the introduction of the new AI-enabled MR Contour DL™ at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2025 Congress in Vienna, Austria. The company will also showcase its updated Intelligent Radiation Therapy (iRT), a software solution that standardizes complex workflows, helping to enable a shorter timeline from diagnosis to treatment and more precise radiation therapy. According to the World Health Organization (WHO), cancer conti
Revenue growth was 3% year-over-year; Organic revenue growth* was 4% Net income margin was 11.8% versus 8.0% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.0% versus 14.7% Diluted earnings per share (EPS) were $1.23 versus $0.81 for the prior year; Adjusted EPS* was $1.01 versus $0.90 Cash flow from operating activities was $250 million versus $419 million for the prior year; Free cash flow* was $98 million versus $274 million Updates full-year 2025 guidance Board of Directors authorizes a $1 billion share repurchase program GE HealthCare (NASDAQ:GEHC) today reported financial results for the first quarter ended March 31, 2025. GE He
GE HealthCare (NASDAQ:GEHC) is announcing that members of its management team will present at the following upcoming investor conferences. Bank of America Securities Healthcare Conference in Las Vegas, NV – May 13, 2025 at 10:00 am CT / 11:00 am ET Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL – June 10, 2025 at 9:00 am CT / 10:00 am ET Webcasts of these events can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the dates and times listed above. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical
Pristina Via™ mammography system is designed to enhance the mammography experience with advanced diagnostic tools and streamlined exam workflows GE HealthCare will distribute DeepHealth's SmartMammo™, now commercially available in the U.S., to harness the power of AI to streamline radiology workflows Invenia™ Automated Breast Ultrasound (ABUS) Premium is the first FDA-approved breast ultrasound supplemental screening technology specifically designed for detecting cancer in dense breasts SenoBright™ HD and SerenaBright™ are the first FDA-cleared Contrast Enhanced Mammography (CEM) and CEM biopsy solutions designed to complement mammograms with functional insights GE HealthCare (NASD
GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno
This strategic research collaboration – known as a Care Innovation Hub – will bring together clinicians and researchers from Cincinnati Children's with clinical scientists and engineers from GE HealthCare to work together on projects that aim to develop the next generation of pediatric medical imaging in MR, CT, molecular imaging, ultrasound, and more. Research developed as part of the collaboration will aim to improve the consistency of care delivered by all pediatric care providers to help address unmet needs in pediatric medicine Cincinnati Children's and GE HealthCare (NASDAQ:GEHC) will form a strategic research program focused on driving clinical and technical research to advance
GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 2, 2025 /PRNewswire/ -- Equity Insider News Commentary – Artificial Intelligence (AI) is quickly becoming a major force in healthcare, as use of AI applications in medical fields is growing rapidly. Researchers at Dartmouth recently conducted the first clinical trial of a therapy chatbot powered by generative AI (genAI), and found that it resulted in significant improvements in participants' symptoms. Cleveland Clinic and UAE-based G42 recently started collaborating on the advancement of even more AI in healthcare adoption, signalling an international push in this revolution. Because of this, the
GE HealthCare has completed its acquisition of Sumitomo Chemical's 50% stake in Nihon Medi-Physics (NMP), giving it full ownership. As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease Kevin O'Neill, President & CEO of GE HealthCare's Pharmaceutical Diagnostics segment, will also become President of NMP. GE HealthCare Technologies Inc. (GE HealthCare or the Company) (NASDAQ:GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As
Revenue growth was 3% year-over-year; Organic revenue growth* was 4% Net income margin was 11.8% versus 8.0% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.0% versus 14.7% Diluted earnings per share (EPS) were $1.23 versus $0.81 for the prior year; Adjusted EPS* was $1.01 versus $0.90 Cash flow from operating activities was $250 million versus $419 million for the prior year; Free cash flow* was $98 million versus $274 million Updates full-year 2025 guidance Board of Directors authorizes a $1 billion share repurchase program GE HealthCare (NASDAQ:GEHC) today reported financial results for the first quarter ended March 31, 2025. GE He
GE HealthCare (NASDAQ:GEHC) will announce its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2025 payable on May 15, 2025 to all shareholders of record as of April 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than
Fourth Quarter 2024 Revenue growth was 2% year-over-year; Organic revenue growth* was 2% Net income margin was 13.5% versus 7.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 18.7% versus 16.1% Diluted earnings per share (EPS) were $1.57 versus $0.88 for the prior year; Adjusted EPS* was $1.45 versus $1.18 Cash flow from operating activities was $913 million versus $1.1 billion for the prior year; Free cash flow* was $811 million versus $956 million Full Year 2024 Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 10.1% versus 8.0% for the prior year; Adjusted EBIT margin* was 16.3% versus 15.1
GE HealthCare (NASDAQ:GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digit
Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.
Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4% Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99 Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* was $651 million versus $570 million Company raises low end of full-year 2024 Adjusted EBIT margin* and Adjusted EPS* guidance with continued execution; trending toward the lower end of Organic revenue growth* range GE HealthCare (NASDAQ:GEHC) today repor
GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions inno
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, c
Revenues were flat year-over-year; Organic revenue growth* was 1% Net income margin was 8.9% versus 8.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.3% versus 14.8% Diluted earnings per share (EPS) were $0.93 versus $0.91 for the prior year; Adjusted EPS* was $1.00 versus $0.92 Cash flow from operating activities was $(119) million versus $(67) million for the prior year; Free cash flow* was $(182) million versus $(136) million Company updates full-year guidance for Organic revenue growth* and Adjusted EBIT margin* GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2024. GE HealthCare
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00
Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously
Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously
UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously
BTIG Research upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00
JP Morgan initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $90.00
Stifel initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00
Goldman initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $87.00
HSBC Securities initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $88.00 from $66.00 previously
10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
DEFA14A - GE HealthCare Technologies Inc. (0001932393) (Filer)
DEF 14A - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
10-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)